Pigmented Villonodular Synovitis Drug Market
Global Pigmented Villonodular Synovitis Drug Market Size, Share & Trends Analysis Report By Type (Cabiralizumab, Emactuzumab, Mcs-110, And Nilotinib), And By Application (Hospital, Clinic And Other) Forecast 2022-2028 Update Available - Forecast 2024-2030
The global pigmented villonodular synovitis drug market is anticipated to grow at a considerable CAGR. pigmented villonodular synovitis was first described as an inflammatory process of joints. It causes blood vessels to stop blood flow which in turn leads to hemorrhage. It causes repeated mild trauma in the joints. Pigmented villonodular synovitis is a neoplastic origin as traits of cytogenetic aberrations are found in most of the hypotheses. There is a consistent rearrangement in this ailment in chromosomes 1p11-13. It is a rare condition and is accompanied by pain in joints. In some cases, swelling of joints is also seen. For instance, in Nov 2020, SyNox therapeutics Ltd who is a manufacturer of emactuzumab has been granted funds by Healthcap and Medicxi. This will help SyNox to grow more in the development of drugs for tenosynovial giant cell tumors which are also known as pigmented villonodular synovitis.
Impact of COVID-19 Pandemic on Global Pigmented Villonodular synovitis drug Market
Covid-19 Pandemic has affected every sector of the world in some way. Pigmented villonodular synovitis drug market was affected due to the nationwide lockdown in all parts of the world. Due to this medical facility and drugs were not in reach to people and diagnosis was not possible. Being a rare disease, Pigmented villonodular synovitis could be treated under the medical supervision of experts which was not available during covid-19.
Segmental Outlook
The global pigmented villonodular synovitis drug market is segmented based on type and application. Based on type, the market is segmented into Cabiralizumab, Emactuzumab, Mcs-110, And Nilotinib. Based on application the market is sub-segmented into Hospital, Clinic, And Other. Among these, hospital segment is likely to show fastest growth in the market during the forecast period. the factors such as increasing in-patients in hospitals related suffering from rare condition and demand for advanced treatment are factors expected to drive the growth of segment.
Global Pigmented Villonodular Synovitis Drug Market Share by type, 2021 (%)
Emactuzumab is Anticipated to Hold a Prominent Share in the Global Pigmented villonodular synovitis drug Market
Emactuzumab is anticipated to hold a prominent market share in the global pigmented villonodular synovitis drug market during the forecast period. Emactuzumab is a type of antibody developed by clinical experts in collaboration with pharma companies to reduce macrophages in tumor tissue mainly in joints. Tumor-causing macrophages are present in areas where there is an abnormal growth in tissue. Macrophages suppress immune system functions in the body which in turn promote tumor cells to grow. For instance, in Aug 2020, Celleron therapeutics which is a company based in UK has entered into a license agreement with Roche. This agreement has provided global rights to the company for clinical development and commercialization of emactuzumab.
Regional Outlooks
The global pigmented villonodular synovitis drug market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). North America is anticipated to lead the pigmented villonodular synovitis drug market during the forecast period.
Global Pigmented villonodular synovitis drug Market Growth, by Region 2022-2028
North America is Estimated to Hold the Major Share in the Global Pigmented villonodular synovitis drug Market
Geographically, it is anticipated that the major share of the market will be taken by North America and this region will lead during the forecast period. Increasing cases of cancer in the US is a major cause of this market growth. According to a paper published in the American cancer society journal, there were around 1.8 million new cancer cases that came up in the US. The same source also states around 606,520 cancer deaths happened in the US in the year 2020. In the year 2020, in the US there were around 89,500 cancer cases diagnosed in adolescents. For instance, in Nov 2021, AmMax Bio, Inc. which is a clinical biotech company will host a webinar on how AMB-05X can be used for the treatment of tenosynovial giant cell tumors. AmMax Bio also has its proprietory CSF1R monoclonal antibody platform.
Market Players Outlook
The major companies serving the global pigmented villonodular synovitis drug market include Bristol- Myers Squibb Company, F.Hoffmann-La Roche Ltd., Novartis AG, Plexxicon, Inc., Abbott Laboratories, and others. The market players are adopting different market strategies such as mergers and acquisitions, new product launches, business expansion, partnership collaboration, and others. For instance, in Nov 2020, Deciphera Pharmaceuticals Inc. announced results acquired by an ongoing study of oral inhibitor kinase of CSF1R for those patients suffering from tenosynovial giant cell tumors. This study was about DCC-3014 in advanced solid tumors.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Pigmented villonodular synovitis drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on The Global Pigmented villonodular synovitis drugs Market
• Recovery Scenario of Global Pigmented villonodular synovitis drugs Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Bristol-Myers Squibb Company
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. F.Hoffmann-La Roche Ltd
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Novartis AG
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Plexxicon Inc.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Abbott Laboratories
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Pigmented villonodular synovitis drug Market by type
4.1.1. Cabiralizumab
4.1.2. Emactuzumab
4.1.3. Mcs-110
4.1.4. Nilotinib
4.2. Global Pigmented villonodular synovitis drugs Market by Application
4.2.1. Hospital
4.2.2. Clinic
4.2.3. Others
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Apexigen, Inc.
6.2. SyNox Therapeutics Ltd.
6.3. Five Prime Therapeutics
6.4. Amgen Inc.
6.5. Takeda Pharmaceutical company Ltd.
1. GLOBAL PIGMENTED VILLONODULAR SYNOVITIS DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL CABIRALIZUMAB PIGMENTED VILLONODULAR SYNOVITIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL EMACTUZUMAB PIGMENTED VILLONODULAR SYNOVITIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL MCS-110 PIGMENTED VILLONODULAR SYNOVITIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL NILOTINIB PIGMENTED VILLONODULAR SYNOVITIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
7. GLOBAL HOSPITAL PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL CLINIC PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL OTHER PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
11. NORTH AMERICAN PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
13. NORTH AMERICAN PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
14. EUROPEAN PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
15. EUROPEAN PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
16. EUROPEAN PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
17. ASIA-PACIFIC PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET RESEARCH AND ANALYSIS TYPE, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
20. REST OF THE WORLD PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. REST OF THE WORLD PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
22. REST OF THE WORLD PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET, 2021-2027 (%)
4. GLOBAL PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL CABIRALIZUMAB PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL EMACTUZUMAB PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL MCS-110 PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL NILOTINIB PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL OTHER PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
11. GLOBAL HOSPITAL PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL CLINIC PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL OTHER PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. US PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
16. CANADA PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
17. UK PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
18. FRANCE PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
19. GERMANY PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
20. ITALY PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
21. SPAIN PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
22. REST OF EUROPE PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
23. INDIA PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
24. CHINA PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
25. JAPAN PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
26. SOUTH KOREA PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF ASIA-PACIFIC PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF THE WORLD PIGMENTED VILLONODULAR SYNOVITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
